Apellis Pharmaceuticals (NASDAQ:APLS) Insider Caroline Baumal Sells 2,797 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Caroline Baumal sold 2,797 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $60,890.69. Following the sale, the insider directly owned 86,527 shares of the company’s stock, valued at $1,883,692.79. This represents a 3.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Caroline Baumal also recently made the following trade(s):

• On Tuesday, January 20th, Caroline Baumal sold 1,882 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $19.79, for a total value of $37,244.78.

Apellis Pharmaceuticals Trading Down 1.1%

APLS traded down $0.25 on Friday, reaching $21.76. 2,214,978 shares of the company traded hands, compared to its average volume of 3,258,745. The company has a market cap of $2.75 billion, a P/E ratio of 70.18 and a beta of 0.31. The company has a quick ratio of 3.10, a current ratio of 3.54 and a debt-to-equity ratio of 0.90. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $30.91. The firm has a fifty day simple moving average of $22.99 and a two-hundred day simple moving average of $23.49.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. The business had revenue of $458.58 million for the quarter, compared to the consensus estimate of $364.58 million. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business’s revenue was up 133.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.46) EPS. As a group, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Key Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re?rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near?term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Institutional Trading of Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of APLS. Parallel Advisors LLC lifted its position in Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after buying an additional 855 shares during the last quarter. Jones Financial Companies Lllp boosted its position in shares of Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after purchasing an additional 1,373 shares during the period. Osaic Holdings Inc. boosted its position in shares of Apellis Pharmaceuticals by 141.2% during the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after purchasing an additional 1,570 shares during the period. Allworth Financial LP increased its holdings in Apellis Pharmaceuticals by 64.1% in the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after purchasing an additional 857 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Apellis Pharmaceuticals in the third quarter valued at approximately $64,000. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on APLS. William Blair reaffirmed an “outperform” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 15th. Wolfe Research initiated coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 6th. They issued a “peer perform” rating for the company. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $19.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, January 12th. HC Wainwright dropped their target price on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Finally, TD Cowen cut their price target on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Twelve equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.53.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.